Is 505(b)(2) filing a safer strategy: avoiding a known risk? Online publication date: Sat, 26-Jul-2014
by Vure Prasad; Moumita Biswas; Sagar Vishal
International Journal of Intellectual Property Management (IJIPM), Vol. 7, No. 1/2, 2014
Abstract: 505(b)(2) application is one of the three established types of regulatory submission and may be advantageous for pharmaceutical sponsors. The 505(b)(2) regulatory submission is defined in FFDC act as an NDA containing investigations of safety and effectiveness, mostly relied upon by the applicant for approval of such NDA but were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. In most 505(b)(2) cases, safety and efficacy information of the (RLD), both in terms of non-clinical and clinical portion, are relied upon, while minute additional data required to establish comparability with the RLD, are worked out. The present paper is an analysis on how 505(b)(2) submissions by developing different alternatives, and are considered as an effective, safer filing route in terms obtaining a approval in shorter duration, avoiding known possible risk and facilitating early launch possibility with a lower cost.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook